Chouinard G, Annable L, Ross-Chouinard A, Mercier P
Clinical Psychopharmacology Unit, Allan Memorial Institute, Royal Victoria Hospital, Montreal, Quebec, Canada.
J Clin Psychopharmacol. 1988 Aug;8(4 Suppl):21S-26S.
In a 5-year longitudinal study in a cohort of 169 schizophrenic outpatients treated with neuroleptics, we found a twofold increase (from 22% to 44%) in prevalence of tardive dyskinesia (TD) meeting the Schooler and Kane research diagnostic criteria. If we include cases of TD that were considered definite but did not meet the research criteria, the prevalence increased from 31% to 58%. In the cohort of 131 patients who did not present with the disorder in 1975, we found parkinsonism and increase in parkinsonism to be the best predictors of subsequent development of the disorder. Poor schizophrenic prognosis and long treatment duration also appeared to be risk factors. Another finding was the importance of changes in neuroleptic and antiparkinsonian dosage in both covering and uncovering TD.
在一项针对169名接受抗精神病药物治疗的精神分裂症门诊患者的5年纵向研究中,我们发现符合斯库勒(Schooler)和凯恩(Kane)研究诊断标准的迟发性运动障碍(TD)患病率增加了两倍(从22%升至44%)。如果将那些虽被认为确诊但不符合研究标准的TD病例包括在内,患病率则从31%升至58%。在1975年未出现该疾病的131名患者队列中,我们发现帕金森症以及帕金森症加重是该疾病后续发展的最佳预测因素。精神分裂症预后不良和治疗时间长似乎也是风险因素。另一项发现是,抗精神病药物和抗帕金森药物剂量的变化在掩盖和暴露TD方面都很重要。